Diagenode

The mycotoxin aflatoxin B1 stimulates Epstein–Barr virus-induced B-cell transformation in in vitro and in vivo experimental models


R. Accardi, H. Gruffat, C. Sirand, F. Fusil, T. Gheit, H. Hernandez-Vargas, F. Le Calvez-Kelm, A. Traverse-Glehen, F.-L. Cosset, E. Manet, C. P. Wild and M. Tommasino

Although Epstein–Barr virus (EBV) infection is widely distributed, certain EBV-driven malignancies are geographically restricted. EBV-associated Burkitt’s lymphoma (eBL) is endemic in children living in sub-Saharan Africa. This population is heavily exposed to food contaminated with the mycotoxin aflatoxin B1 (AFB1). Here, we show that exposure to AFB1 in in vitro and in vivo models induces activation of the EBV lytic cycle and increases EBV load, two events that are associated with an increased risk of eBL in vivo. AFB1 treatment leads to the alteration of cellular gene expression, with consequent activations of signalling pathways, e.g. PI3K, that in turn mediate reactivation of the EBV life cycle. Finally, we show that AFB1 triggers EBV-driven cellular transformation both in primary human B cells and in a humanized animal model. In summary, our data provide evidence for a role of AFB1 as a co-factor in EBV-mediated carcinogenesis

Tags
Article alert

Share this article

Published
September, 2015

Source

Products used in this publication

  • ChIP kit icon
    C01010051
    iDeal ChIP-seq kit for Histones
  • ChIP kit icon
    C01010055
    iDeal ChIP-seq kit for Transcription Factors

Events

 See all events

News

 See all news


The European Regional Development Fund and Wallonia are investing in your future.

Extension of industrial buildings and new laboratories.


       Site map   |   Contact us   |   Conditions of sales   |   Conditions of purchase   |   Privacy policy   |   Diagenode Diagnostics